VOLUME 30 - NUMBER 51 - 2009

Preliminary analysis of 30 consecutive neoadjuvant chemotherapy treatments for operable Advanced Gastric Cancer (AGC)

  • Tamburini A., Orsenigo E., Gazzetta P., Mazza E., Di Palo S., Staudacher C.
  • Articolo Originale, 239-239
  • Full text PDF

  • Introduction: Gastric cancer remains one of the world’s most commonly diagnosed cancers. Standard treatment for highly Advanced Gastric Cancer (AGC) has not been established yet. NeoAdjuvant Chemotherapy (NAC) represents a promising approach, which may improve the prognosis of AGC. Methods: Results for a series of 30 consecutive patients with AGC treated with ECF induction chemotherapy since January 2008 were analyzed retrospectively. Results: The primary tumor was resected in 23 of the 30 patients (resectability, 85.2%). Progression of the disease during chemotherapy was observed in 1 patient only (3,3%). No treatment-related deaths occurred, and serious adverse effects (grade 3-4) were noted in only 13,3 % of the patients. Curative (R0) resection was possible in 20 patients. The downstaging rate was 86.9% (20/23), resulting in a significantly improved prognosis for the downstaged patients (P = 0.012). Conclusion: Induction chemotherapy for AGC appears to be well tolerated, safe and promising treatment.

  • KEY WORDS: advanced gastric cancer, neoadjuvant chemotherapy.